P-82 IMPACT OF HEPATITIS C VIRUS ERADICATION WITH DIRECT ANTIVIRAL DRUGS ON GLYCEMIC CONTROL AFTER LIVER TRANSPLANTATION

No Liver transplant patients have increased risk of type 2 diabetes (T2DM). Although hepatitis C virus (HCV) is an independent risk factor for insulin resistance and T2DM, there is no consensus on the impact of antiviral treatment on sustained glycemic control, particularly in liver transplant patients with HCV (HCV-LT). Objective: Evaluate the impact of viral HCV eradication with direct antiviral drugs on long term glycemic control of HCV-liver transplanted (HCV-LT) patients. A retrospective cohort of HCV-LT recipients with sustained virological response (SVR) after direct-antiviral treatment (DAA) was included in this longitudinal study. Clinical and laboratory data were collected before antiviral treatment and sequentially after SVR. A Cox Regression analysis was performed to evaluate the variables associated with glycated hemoglobin (A1C) on target (≤ 7% and ≤ 5.6% with and without T2DM) at the end of the follow-up period. Overall, 140 eligible HCV-LT patients were included (64% male, 63 ± 9 yrs, 15% with BMI ≥ 30 kg/m2, 64% with T2DM) and followed for 43 (19-70) months. After LT, 79% used tacrolimus, 34% Sirolimus and 14% prednisone. Before treatment 71% had A1C on target. At follow up this rate increased to 77%, with add-on insulin/increased doses in 14%, withdraw/reduced doses in 12% and diet/oral treatment in 76% of HCV-LT patients. On multivariate Cox analysis, A1C on target at follow-up were independently associated with diet/oral treatment (HR:2.77; 95%CI,1.33-5.78;p=0.006) and time between LT and end of DAA treatment (HR:0.996; 95%CI,0.992-1.000;p=0.045), adjusted for age, gender, weight gain and immunosuppressants. Over 70% of HCV-LT patients with SVR remained in good glycemic control over time, which was associated with initial and long-lasting non-insulin treatment. Of note, A1C on target was inversely associated with time from transplant to the end of DAA and subsequent HCV eradication, despite other important factors for long-term glycemic control.

Authors

Institutions

Publication Details

Journal
Annals of Hepatology
Published
2024-12-01
DOI
https://doi.org/10.1016/j.aohep.2024.101696
Primary Topic
Liver Disease Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

P-82 IMPACT OF HEPATITIS C VIRUS ERADICATION WITH DIRECT ANTIVIRAL DRUGS ON GLYCEMIC CONTROL AFTER LIVER TRANSPLANTATION

Claudia Cristina Tavares de Souza, Eduardo de Souza Martins Fernandes, Nathalie Carvalho Leite, S. Bastos et al.
Annals of Hepatology
Liver Disease Diagnosis and Treatment
article

P-82 IMPACT OF HEPATITIS C VIRUS ERADICATION WITH DIRECT ANTIVIRAL DRUGS ON GLYCEMIC CONTROL AFTER LIVER TRANSPLANTATION

Claudia Cristina Tavares de Souza, Eduardo de Souza Martins Fernandes, Nathalie Carvalho Leite, S. Bastos, Henrique Sérgio Moraes Coelho, Alicia Araújo de Oliveira, Cristiane Alves Villela‐Nogueira
article en

Abstract

No Liver transplant patients have increased risk of type 2 diabetes (T2DM). Although hepatitis C virus (HCV) is an independent risk factor for insulin resistance and T2DM, there is no consensus on the impact of antiviral treatment on sustained glycemic control, particularly in liver transplant patients with HCV (HCV-LT). Objective: Evaluate the impact of viral HCV eradication with direct antiviral drugs on long term glycemic control of HCV-liver transplanted (HCV-LT) patients. A retrospective cohort of HCV-LT recipients with sustained virological response (SVR) after direct-antiviral treatment (DAA) was included in this longitudinal study. Clinical and laboratory data were collected before antiviral treatment and sequentially after SVR. A Cox Regression analysis was performed to evaluate the variables associated with glycated hemoglobin (A1C) on target (≤ 7% and ≤ 5.6% with and without T2DM) at the end of the follow-up period. Overall, 140 eligible HCV-LT patients were included (64% male, 63 ± 9 yrs, 15% with BMI ≥ 30 kg/m2, 64% with T2DM) and followed for 43 (19-70) months. After LT, 79% used tacrolimus, 34% Sirolimus and 14% prednisone. Before treatment 71% had A1C on target. At follow up this rate increased to 77%, with add-on insulin/increased doses in 14%, withdraw/reduced doses in 12% and diet/oral treatment in 76% of HCV-LT patients. On multivariate Cox analysis, A1C on target at follow-up were independently associated with diet/oral treatment (HR:2.77; 95%CI,1.33-5.78;p=0.006) and time between LT and end of DAA treatment (HR:0.996; 95%CI,0.992-1.000;p=0.045), adjusted for age, gender, weight gain and immunosuppressants. Over 70% of HCV-LT patients with SVR remained in good glycemic control over time, which was associated with initial and long-lasting non-insulin treatment. Of note, A1C on target was inversely associated with time from transplant to the end of DAA and subsequent HCV eradication, despite other important factors for long-term glycemic control.

Annals of HepatologyVol. 29
Universidade Federal do Rio de Janeiro (BR), Hospital São Vicente de Paulo (BR), Universidade Federal do Estado do Rio de Janeiro (BR)
Good health and well-being
Openalex Percentile: Top 67%
Liver Disease Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.